Israel-based Teva Pharmaceuticals will sell its remaining women's health assets in two deals, totaling $1.38 billion, according to the Philadelphia Business Journal.
In one deal, Foundation Consumer Healthcare will acquire Teva's emergency contraception products, including Plan B One-Step and Next Choice One Dose, for $675 million.
Teva will sell its remaining contraception, fertility, menopause and osteoporosis products to CVC Capital Partners Fund VI for $703 million in cash.
Teva will use the money from these deals, along with proceeds from the recent $1.1 billion sale of its intrauterine device, to pay off some loan debt, according to the report.
The deals are expected to close by the end of the year.